July 1, 2002Arteriosclerosis Thrombosis and Vascular Biology
Angiotensin II Type 1 Receptor Antagonism Improves Hypercholesterolemia-Associated Endothelial Dysfunction
Why the study?
Does candesartan improve endothelial function and serum inflammation markers in hypercholesterolemic patients?
Population
47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)
Comparison
Candesartan 16 mg/d for 6 weeks vs Placebo or felodipine 5 mg/d for 6 weeks
Design
Other
Follow-up
6 weeks
Authors
Discussion
Loading...
Member takes
Implication
Candesartan improves endothelial function in hypercholesterolemia independent of BP effects; confirms AT1 antagonism benefits beyond vasodilation or lipids.
Structured PICO
Does candesartan improve endothelial function and serum inflammation markers in hypercholesterolemic patients?
P
Population
47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)
I
Intervention
Candesartan 16 mg/d for 6 weeks
C
Comparator
Placebo or felodipine 5 mg/d for 6 weeks
O
Outcome
Endothelial function assessed by measurement of forearm blood flow (FBF) by venous occlusion plethysmographysurrogate
AT1 receptor antagonism with candesartan improves endothelial function and reduces markers of oxidative stress and inflammation in hypercholesterolemic patients, independent of lipid or blood pressure lowering.
Cite This Study
Waßmann et al. (2002) studied this question.